Quantcast
Home > Quotes > EIDX

Eidos Therapeutics, Inc. Common Stock (EIDX) Quote & Summary Data

EIDX 
$14.21
*  
0.13
0.92%
Get EIDX Alerts
*Delayed - data as of Nov. 20, 2018  -  Find a broker to begin trading EIDX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / $ 14
1 Year Target
28.5
Today's High / Low
$ 14.50 / $ 13.6775
Share Volume
76,545
50 Day Avg. Daily Volume
158,343
Previous Close
$ 14.08
52 Week High / Low
$ 24.75 / $ 8.89
Market Cap
522,177,456
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
3.14

Intraday Chart

Shares Traded

Share Volume:
76,545
50 Day Avg. Daily Volume:
158,343

Trading Range

The current last sale of $14.21 is 59.84% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 14.50 $ 24.75
 Low: $ 13.6775 $ 8.89

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases by targeting them at their collective source by stabilizing TTR. TTR is a protein that occurs naturally in the form of a tetramer (a molecular structure consisting of four identical subunits, or monomers) and performs multiple beneficial roles, including the transport of essential hormones and vitamins. Over 25 years of research have shown that ATTR is uniformly driven by destabilization of the TTR tetramer, stemming from either specific gene mutations or aging. TTR destabilization drives an irreversible dissociation of the tetramer into monomers, which subsequently aggregate and deposit predominantly in the heart and peripheral nervous system, leading to organ damage, loss of organ function, and eventual death if left untreated.  ... More ...  


Risk Grade

Where does EIDX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.96
Open Date:
Nov. 20, 2018
Close Price:
$ 14.08
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x